Another case of PML hits the MS drug Tysabri
PML is a rare demylinating disease that occurs in 6 per 10 million patients. This is the third case that is associated with Tysabri. Investors are not happy.
ADVERTISEMENT
More in Uncategorized
Past Week
-
My wife’s story: How DEA and CDC guidelines destroyed our golden years
-
The gastroenterologist shortage: Why supply is falling behind demand
-
Health care as a human right vs. commodity: Resolving the paradox
-
Why voicemail in outpatient care is failing patients and staff
-
Alex Pretti’s death: Why politics belongs in emergency medicine
-
U.S. opioid policy history: How politics replaced science in pain care
-
Past 6 Months
-
How environmental justice and health disparities connect to climate change
-
Will AI replace primary care physicians?
-
A physician father on the Dobbs decision and reproductive rights
-
What is the minority tax in medicine?
-
Why the U.S. health care system is failing patients and physicians
-
Alex Pretti: a physician’s open letter defending his legacy
-
Recent Posts
-
AI censorship threatens the lifeline of caregiver support [PODCAST]
-
Demedicalize dying: Why end-of-life care needs a spiritual reset
-
Physician due process: Surviving the court of public opinion
-
Spaced repetition in medicine: Why current apps fail clinicians
-
When the doctor becomes the patient: a breast cancer diagnosis
-
My journey with fibroids and hysterectomy: a patient’s perspective
-
Subscribe to KevinMD and never miss a story!
Get free updates delivered free to your inbox.
